Thromb Haemost 2016; 116(04): 764-771
DOI: 10.1160/TH16-03-0248
Atherosclerosis and Ischaemic Disease
Schattauer GmbH

Association between anti-apolipoprotein A-1 antibodies and cardiovascular disease in the general population

Results from the CoLaus study
Panagiotis Antiochos
1   Department of Internal Medicine, University Hospital of Lausanne, Lausanne, Switzerland
,
Pedro Marques-Vidal
1   Department of Internal Medicine, University Hospital of Lausanne, Lausanne, Switzerland
,
Julien Virzi
2   Division of Laboratory Medicine, Department of Genetics and Laboratory Medicine, Geneva University Hospitals, Geneva, Switzerland
3   Department of Human Protein Sciences, Faculty of Medicine, University of Geneva, Geneva, Switzerland
,
Sabrina Pagano
2   Division of Laboratory Medicine, Department of Genetics and Laboratory Medicine, Geneva University Hospitals, Geneva, Switzerland
3   Department of Human Protein Sciences, Faculty of Medicine, University of Geneva, Geneva, Switzerland
,
Nathalie Satta
2   Division of Laboratory Medicine, Department of Genetics and Laboratory Medicine, Geneva University Hospitals, Geneva, Switzerland
3   Department of Human Protein Sciences, Faculty of Medicine, University of Geneva, Geneva, Switzerland
,
François Bastardot
1   Department of Internal Medicine, University Hospital of Lausanne, Lausanne, Switzerland
,
Oliver Hartley
4   Department of Pathology and Immunology, Faculty of Medicine, University of Geneva, Geneva, Switzerland
,
Fabrizio Montecucco
2   Division of Laboratory Medicine, Department of Genetics and Laboratory Medicine, Geneva University Hospitals, Geneva, Switzerland
5   Division of Cardiology, Foundation for Medical Researches, Department of Medical Specialties, University of Geneva, Geneva, Switzerland
,
François Mach
5   Division of Cardiology, Foundation for Medical Researches, Department of Medical Specialties, University of Geneva, Geneva, Switzerland
,
Gerard Waeber
1   Department of Internal Medicine, University Hospital of Lausanne, Lausanne, Switzerland
,
Peter Vollenweider
1   Department of Internal Medicine, University Hospital of Lausanne, Lausanne, Switzerland
,
Nicolas Vuilleumier
2   Division of Laboratory Medicine, Department of Genetics and Laboratory Medicine, Geneva University Hospitals, Geneva, Switzerland
3   Department of Human Protein Sciences, Faculty of Medicine, University of Geneva, Geneva, Switzerland
› Author Affiliations

Financial support: This work was supported by the Leenaards Foundation, the Faculty of Biology and Medicine of Lausanne and the Swiss National Science Foundation [grant numbers 3200B0–105993, 3200B0–118308, 33CSCO–122661, 33CS30–139468 and 33CS30–148401, 310030–163335]. PV and GW received unrestricted research grants from GlaxoSmithKline to build the CoLaus Study.
Further Information

Publication History

Received: 29 March 2016

Accepted after major revision: 01 June 2016

Publication Date:
20 November 2017 (online)

Preview

Summary

We aimed to determine the association between autoantibodies against apolipoprotein A-1 (anti-apoA-1 IgG) and prevalent cardiovascular (CV) disease (CVD) as well as markers of CV risk in the general population. Cross-sectional data were obtained from 6649 subjects (age 52.6 ± 10.7 years, 47.4 % male) of the population-based CoLaus study. CVD was defined as myocardial infarction, angina pectoris, percutaneous revascularisation or bypass grafting for ischaemic heart disease stroke or transient ischaemic attack, and was assessed according to standardised medical records. Anti-apoA-1 IgG and biological markers were measured by ELISA and conventional automated techniques, respectively. Prevalence of high anti-apoA-1 IgG levels in the general population was 19.9 %. Presence of anti-apoA-1 IgG was significantly associated with CVD [odds ratio 1.34, 95 % confidence interval (1.05–1.70), p=0.018], independently of established CV risk factors (CVRFs) including age, sex, hypertension, smoking, diabetes, low and high-density lipoprotein cholesterol levels. The n=455 (6.8 %) study participants with a history of CVD (secondary prevention subgroup) presented higher median anti-ApoA-1 IgG values compared with subjects without CVD (p=0.029). Among patients in the secondary prevention subgroup, those with positive anti-apoA-1 IgG levels had lower HDL (p=0.002) and magnesium (p=0.001) levels, but increased uric acid and high-sensitivity C-reactive protein levels (p=0.022, and p<0.001, respectively) compared to patients with negative anti-apoA-1 IgG levels. In conclusion, anti-apoA-1 IgG levels are independently associated with CVD in the general population and also related to CV biomarkers in secondary prevention. These findings indicate that anti-apoA-1 IgG may represent a novel CVRF and need further study in prospective cohorts.